Universal Health Services (UHS): Why Analysts Are Calling It One of NYSE's Most Undervalued Plays
Universal Health Services Inc. (NYSE: UHS) is drawing attention from analysts who have pegged it as one of the more attractive undervalued stocks on the New York Stock Exchange. The hospital chain reported results for the first quarter of 2026 on April 29, showing net revenue of $4.495 billion, a 9.6% increase year over year, while net income attributable to the company rose to $348.7 million, or $5.65 per diluted share, compared with $316.7 million, or $4.80 per diluted share, in the same period last year.
Adjusted net income came in at $346.5 million, or $5.62 per share, up from $319.5 million, or $4.84 per share, a year earlier. The company’s EBITDA excluding noncontrolling interests reached $651.7 million, compared with $603.9 million in the prior-year quarter, while adjusted EBITDA net of NCI climbed to $648.3 million from $598.2 million. The improvements span both top-line growth and margin expansion, underscoring what analysts describe as solid operational execution.
UHS operates more than 400 acute care hospitals, behavioral health facilities, outpatient centers and ambulatory care access points across the United States, Puerto Rico and the United Kingdom. The company’s footprint in behavioral health, in particular, positions it to benefit from rising demand for mental health services, a trend that has accelerated since the pandemic. Meanwhile, patient volumes at its acute care hospitals have remained resilient, supported by population aging and higher utilization rates.
From a valuation standpoint, shares trade at a discount to historical multiples and relative to some large-cap healthcare peers, which is why several analysts have flagged the stock as a potential value opportunity. The latest quarterly results reinforce the thesis that the company can sustain its revenue and earnings momentum even as the broader economy faces headwinds. That said, investors should weigh the company’s exposure to payer mix shifts and regulatory changes in the healthcare sector.
While UHS presents a compelling case for value-oriented investors, some market observers note that certain AI-related stocks may offer even higher upside, particularly given the onshoring trend and tariff policies under the current administration. For those seeking an extremely undervalued AI stock that could benefit from these dynamics, a free report on the best short-term AI stock is available.
Read Next: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.